DexCom(US:DXCM) Globenewswire·2025-11-24 20:02Core Viewpoint - The Gross Law Firm is notifying shareholders of DexCom, Inc. regarding a class action lawsuit due to allegations of misleading statements and undisclosed material changes to their glucose monitoring products [1][3]. Group 1: Allegations - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes reportedly made the G6 and G7 devices less reliable, posing a material health risk to users who depend on accurate glucose readings [3]. - The enhancements claimed for the G7 device, including its reliability and accuracy, were allegedly overstated by the defendants [3]. - The true scope and severity of the issues related to the G7 devices were downplayed, increasing the risk of regulatory scrutiny and potential legal and financial repercussions for DexCom [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025, with a deadline for shareholders to register for the class action set for December 26, 2025 [3][4]. - Shareholders who register will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors who have suffered losses due to misleading statements or omissions [5].